Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	24^th July 2023

2. INTERESTS AND SHORT POSITIONS

a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,169,030 (1.821%)		-
(2) Derivatives (other than options)	511,000 (0.223%)		511,000 (0.223%)
(3) Options and agreements to purchase/sell	1,582,300 (0.691%)		2,387,500 (1.043%)
Total	6,262,330 (2.735%)		2,898,500 (1.266%)

b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	300	101.18
Purchase	1,977	100.80
Purchase	2,342	100.77
Purchase	867	100.84
Purchase	600	100.87
Purchase	1,900	101.03
Purchase	3,925	101.04
Purchase	59	100.85
Purchase	1,400	101.05
Purchase	379	100.79
Purchase	75	100.73
Purchase	75	100.63
Purchase	1,229	100.76
Purchase	3,600	101.08
Purchase	141	100.70
Purchase	2,911	100.91
Purchase	1,550	101.07
Purchase	1,200	101.10
Purchase	400	100.86
Purchase	255	100.95
Purchase	1,580	101.00
Purchase	1,800	100.81
Purchase	56	100.75
Purchase	1,379	100.96
Purchase	30	100.40
Purchase	333	100.49
Sale	30	100.27
Purchase	807	100.47
Purchase	757	100.50
Purchase	903	100.48
Purchase	200	100.44
Purchase	705	100.40
Purchase	81	100.49
Purchase	171	100.00
Purchase	427	100.54
Purchase	20	100.77
Purchase	526	100.50
Purchase	1,183	100.87
Purchase	162	100.56
Purchase	193	101.04
Purchase	367	100.78
Purchase	78	100.48
Purchase	157	100.51
Purchase	773	100.70
Purchase	744	100.74
Purchase	16	100.62
Purchase	134	100.69
Purchase	232	100.68
Purchase	724	100.52
Purchase	44	100.57
Purchase	889	100.65
Purchase	788	100.53
Purchase	28	100.66
Purchase	593	100.40
Purchase	1,293	100.49
Purchase	300	100.27
Purchase	900	100.38
Purchase	700	100.21
Purchase	988	100.03
Purchase	600	100.42
Purchase	500	100.05
Purchase	532	100.59
Purchase	217	100.80
Purchase	593	100.47
Purchase	361	100.46
Purchase	1,100	100.04
Purchase	782	100.54
Purchase	1,020	100.50
Purchase	1,598	100.45
Purchase	8	100.84
Purchase	100	100.02
Purchase	34	100.87
Purchase	379	100.56
Purchase	111	101.03
Purchase	1	100.85
Purchase	1	101.05
Purchase	348	100.79
Purchase	3	101.01
Purchase	2	101.06
Purchase	314	100.76
Purchase	14,413	100.48
Purchase	1	101.08
Purchase	1	100.70
Purchase	403	100.74
Purchase	13	100.83
Purchase	1,371	100.62
Purchase	4	100.86
Purchase	93	100.69
Purchase	72	100.75
Purchase	273	100.55
Purchase	20	100.41
Purchase	93	100.52
Purchase	206	100.58
Purchase	107	100.57
Sale	300	100.40
Sale	480	100.77

b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c) Options transactions in respect of existing relevant securities

i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Selling	1,000	60.00	American	12/15/2023

ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	25^th July 2023
Contact name	Stephen Glasper
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	100,300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	50,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	29,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	250,000	85.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	119,400	110.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	4,500	110.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	100,000	100.00	American	12/15/2023
IE00BQPVQZ61	Call Option	Written	100,000	110.00	American	12/15/2023
IE00BQPVQZ61	Put Option	Purchased	100,000	85.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	2,800	100.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	2,800	100.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Written	50,000	85.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Purchased	150,000	85.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Purchased	2,600	90.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Purchased	40,900	100.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	200	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	200	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	100,000	70.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	300	100.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Purchased	300	100.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Written	100,000	60.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	16,900	110.00	American	15/09/2023
IE00BQPVQZ61	Call Option	Purchased	533,500	110.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	512,500	115.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	525,000	95.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	520,000	60.00	American	12/15/2023
IE00BQPVQZ61	Put Option	Written	100,000	65.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Purchased	100	100.00	American	28/07/2023
IE00BQPVQZ61	Put Option	Purchased	55,000	70.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	200,000	105.00	American	8/18/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1147812

Time of Receipt (offset from UTC): 20230725T130158+0100